Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 19, 2007

Bayer Schering Pharma to Work on New Imaging Compounds for Neurodegenerative Diseases

  • Bayer Schering Pharma signed a license and option agreement with Taisho Pharmaceutical, Nihon Nohyaku, and the National Institute of Radiological Sciences (NIRS), Japan, to develop imaging compounds for the detection of neurodegenerative diseases. The research will include Alzheimer's disease, Parkinson's disease, and other disorders also associated with neuroinflammation, such as multiple sclerosis.

    "We are convinced that innovations in molecular imaging have the potential to fundamentally improve the diagnosis of neurodegenerative disorders, particularly Alzheimer's disease,” says Hans Maier, head of business unit diagnostic imaging at Bayer Schering Pharma. “Imaging of neuroinflammation as another important pathology will excellently complement these activities. This agreement underscores our commitment to Alzheimer patients by developing innovative diagnostic methods for the early detection of the disease."

    Taisho Pharmaceutical, Nihon Nohyaku, and the NIRS jointly own patent rights for a compound class that may be applied for various noninvasive imaging technologies, such as PET scanning. Under the terms of the agreement Bayer Schering Pharma receives worldwide exclusive rights to develop and market the respective products for use with PET scanning technology.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »